

Clinical trials of perindopril

TrialResults-center www.trialresultscenter.org

1 heart failure

Trial	Treatments	Patients	Trials design and methods
perindopril vs placebo			
Lechat , 1993 n=61/64 follow-up: 3-month	perindopril, 2 mg once daily versus placebo	patients with grade II or III New York Heart Association chronic congestive heart failure on baseline diuretic therapy	double blind
PEP CHF , 2006 n=424/426 follow-up: 26.2 months (range 12-54.2m)	perindopril, 4 mg/day versus placebo	patients aged ≥ 70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease	Parallel groups double blind Europe

More details and results :

- angiotensin-Converting Enzyme Inhibitors for heart failure in all type of heart failure at <http://www.trialresultscenter.org/go-Q43>
- angiotensin-Converting Enzyme Inhibitors for heart failure in elderly at <http://www.trialresultscenter.org/go-Q71>
- inhibition of the renin-angiotensin system (ACEI or ARB) for heart failure in patients with preserved-LVEF heart failure at <http://www.trialresultscenter.org/go-Q234>
- angiotensin-Converting Enzyme Inhibitors for heart failure in patients with preserved-LVEF heart failure at <http://www.trialresultscenter.org/go-Q235>

References

Lechat, 1993:

Lechat P, Garnham SP, Desche P, Bounhoure JP Efficacy and acceptability of perindopril in mild to moderate chronic congestive heart failure. Am Heart J 1993 Sep;126:798-806 [8166887]

Bounhoure JP, Bottineau G, Lechat P, Garnham J, Lapeyre G Value of perindopril in the treatment of chronic congestive heart failure. Multicenter double-blind placebo-controlled study. Clin Exp Hypertens A 1989;11 Suppl 2:575-86 [2691130]

PEP CHF, 2006:

Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, O'Mahony D, Polonski L, Taylor J Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999 Aug;1:211-7 [10935667]

Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006 Oct;27:2338-45 [16963472]

2 diabetes type 2

Trial	Treatments	Patients	Trials design and methods
perindopril vs placebo			
EUROPA (PERSUADE substudy) , 2005 n=721/781 follow-up: 4.3y	perindopril 8mg once daily versus placebo	patients with known coronary artery disease and without heart failure, subgroup of diabetic patients	Parallel groups double-blind
PROGRESS (diabetic subgroup) , 2001 n=393/368 follow-up: 3.9 y	perindopril 4 mg daily versus placebo	hypertensive and non-hypertensive individuals with cerebrovascular disease, subgroup of diabetic patients	Parallel groups double-blind
perindopril and indapamide vs placebo			
ADVANCE , 2007 [NCT00145925] n=NA follow-up:	fixed combination of perindopril and indapamide versus placebo	patients with type 2 diabetes irrespective of initial blood pressure levels or the use of other blood pressure lowering drugs	
ADVANCE , 2007 [NCT00145925] n=5569/5571 follow-up: 4.3 yrs	low-dose fixed combination of perindopril and indapamide versus placebo	individuals with type 2 diabetes	Factorial plan double-blind Asia, Australasia, Europe, and North America

More details and results :

- anti hypertensive agents for diabetes type 2 in patients with or without hypertension at <http://www.trialresultscenter.org/go-Q414>
- angiotensin-receptor blockers for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q427>
- angiotensin renin system blockade for diabetes type 2 in all type of patients at <http://www.trialresultscenter.org/go-Q438>

References

EUROPA (PERSUADE substudy), 2005:

Daly CA, Fox KM, Remme WJ, Bertrand ME, Ferrari R, Simoons ML The effect of perindopril on cardiovascular morbidity and mortality in patients with diabetes in the EUROPA study: results from the PERSUADE substudy. Eur Heart J 2005;26:1369-78 [15860521] 10.1093/eurheartj/ehi225

PROGRESS (diabetic subgroup), 2001:

Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358:1033-41 [[11589932](#)] [10.1016/S0140-6736\(01\)06178-5](#)

Berthet K, Neal BC, Chalmers JP, MacMahon SW, Bousser MG, Colman SA, Woodward M Reductions in the risks of recurrent stroke in patients with and without diabetes: the PROGRESS Trial. Blood Press 2004;13:7-13 [[15083634](#)]

Chapman N, Huxley R, Anderson C, Bousser MG, Chalmers J, Colman S, Davis S, Donnan G, MacMahon S, Neal B, Warlow C, Woodward M Effects of a perindopril-based blood pressure-lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history: the PROGRESS Trial. Stroke 2004 Jan;35:116-21 [[14671247](#)] [10.1161/01.STR.0000106480.76217.6F](#)

Ratnasabapathy Y, Lawes CM, Anderson CS The Perindopril Protection Against Recurrent Stroke Study (PROGRESS): clinical implications for older patients with cerebrovascular disease. Drugs Aging 2003;20:241-51 [[12641480](#)]

ADVANCE, 2007:

Rationale and design of the ADVANCE study: a randomised trial of blood pressure lowering and intensive glucose control in high-risk individuals with type 2 diabetes mellitus. Action in Diabetes and Vascular Disease: PreterAx and DiamicroN Modified-Release Controlled Evaluation. J Hypertens Suppl 2001 Nov;19:S21-8 [[11848259](#)]

Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007 Sep 8;370:829-40 [[17765963](#)]

ADVANCE, 2007:

Chalmers J, Kengne AP, Joshi R, Perkovic V, Patel A New insights from ADVANCE. J Hypertens Suppl 2007;25:S23-30 [[17579315](#)] [10.1097/01.hjh.0000271506.69949.46](#)

Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L, Harrap S, Poulter N, Marre M, Cooper M, Glasziou P, Grobbee DE, Hamet P, Heller S, Liu LS, Mancia G, Mogensen CE, Pan CY, Rodgers A, Williams B Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40 [[17765963](#)] [10.1016/S0140-6736\(07\)61303-8](#)

3 patients at high risk for cardiovascular events

Trial	Treatments	Patients	Trials design and methods
perindopril vs placebo			
EUROPA , 2003 n=6110/6108 follow-up: 4.2y	perindopril 8 mg once daily versus placebo	low-risk patients with stable coronary heart disease and no apparent heart failure	Parallel groups double blind

More details and results :

- angiotensin-Converting Enzyme Inhibitors for patients at high risk for cardiovascular events in all type of patients at <http://www.trialresultscenter.org/go-Q98>
- inhibition of the renin-angiotensin system (ACEI or ARB) for patients at high risk for cardiovascular events in all type of patients at <http://www.trialresultscenter.org/go-Q157>

References

EUROPA, 2003:

Fox KM Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study). Lancet 2003;362:782-8 [13678872]

4 heart failure with preserved LVEF

Trial	Treatments	Patients	Trials design and methods
perindopril vs placebo			
PEP CHF , 2006 n=424/426 follow-up: 26.2 months (range 12-54.2m)	perindopril, 4 mg/day versus placebo	patients aged ≥ 70 years with a diagnosis of heart failure, treated with diuretics and an echocardiogram suggesting diastolic dysfunction and excluding substantial LV systolic dysfunction or valve disease	Parallel groups double blind Europe

More details and results :

- All mechanism for heart failure with preserved LVEF in all type of patients at <http://www.trialresultscenter.org/go-Q237>

References

PEP CHF, 2006:

Cleland JG, Tendera M, Adamus J, Freemantle N, Gray CS, Lye M, O'Mahony D, Polonski L, Taylor J Perindopril for elderly people with chronic heart failure: the PEP-CHF study. The PEP investigators. Eur J Heart Fail 1999 Aug;1:211-7 [10935667]

Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006 Oct;27:2338-45 [16963472]

Entry terms: Perindopril, Pirindopril, Perstarium, S-9490, S 9490, S9490, S 9490-3, S 9490 3, S 94903, Perindopril Erbumine,